Press Detail





Biotest AG:Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp.

Biotest AG / Acquisition/Capital Increase

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp.


Dreieich, 11 September 2007. Biotest AG, Dreieich has acquired the
Biologics business unit ('Nabi Biologics') from Nabi Biopharmaceuticals
Corp., Boca Raton (Florida, USA) in which the company’s plasma protein
operations are pooled, including the company’s headquarters. The purchase
price stands at USD 185 million (approximately EUR 135 million). The
transaction is still subject to merger approval and must also be agreed by
the shareholders of Nabi Biopharmaceuticals.

The Group’s planned entry in the US plasma protein market will therefore be
achieved much faster than was originally anticipated. Nabi Biologics
operates nine plasmapheresis centres in the USA with a production volume of
about 400,000 litres per year as well as a state-of-the-art production
plant. A key product is the hyperimmunoglobulin Nabi-HB® used in the
prevention of hepatitis B. Products currently in clinical development
comprise a polyvalent immunoglobulin (IVIG, Phase III) and Civacir® (Phase
IIb), which is being developed to prevent hepatitis C in liver transplant
patients.

Biotest aims to achieve consolidated sales of at least EUR 380 million for
2008. In the medium term, based on the expected product approval of IVIG in
the USA as well as the expanded capacities in Dreieich, sales for the Group
are set to exceed EUR 500 million.

Financing of the transaction, including repayment of all liabilities due to
banks owed by Biotest AG, is secured by a long-term loan issued by
Commerzbank AG. Deutsche Bank advised Biotest on matters relating to the
transaction. Biotest anticipates that the new US operations will generate
operating income in 2008, which almost matches the additional interest
expenses volume.  We therefore aim to achieve a further increase in the
Group result before tax in 2008. For the current year, Biotest still
expects to record an increase in earnings within the previously announced
range. From 2010 onwards, the US plasma protein business is set to
significantly increase sales and margin quality following the expected
approval of IVIG, and thus contribute to a notably improved Group result.

Biotest AG plans to fund part of the purchase price financing through a
capital increase. Sufficient authorised capital has been made available for
this. The exact conditions of the capital increase will be announced at a
later date. Biotest will therefore continue to maintain its equity-based
financing practice in the accelerated growth stage which now lies ahead.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

Biotest AG: 
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
marion_wendorff@biotest.de
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 
11.09.2007  Financial News transmitted by DGAP
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstr. 5
              63303 Dreieich
              Deutschland
Phone:        +49 - 6103 / 801 - 0
Fax:          +49 - 6103 / 801 - 150
E-mail:       mail@biotest.de
Internet:     www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Indices:      
Listed:       Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
              Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------